NASDAQ:PCVX Vaxcyte Q3 2026 Earnings Report $65.58 -8.24 (-11.16%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vaxcyte EPS ResultsActual EPSN/AConsensus EPS -$2.12Beat/MissN/AOne Year Ago EPSN/AVaxcyte Revenue ResultsActual RevenueN/AExpected Revenue$12.50 millionBeat/MissN/AYoY Revenue GrowthN/AVaxcyte Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateWednesday, November 4, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Vaxcyte Earnings HeadlinesVaxcyte (NASDAQ:PCVX) Sees Large Volume Increase on Analyst Upgrade21 minutes ago | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Given New $122.00 Price Target at Needham & Company LLCOctober 6 at 2:03 AM | americanbankingnews.comA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.October 6 at 1:00 AM | Investors Alley (Ad)PCVX stock hits fresh 52-week high on late-stage win in adult pneumonia vaccine race: Jefferies says it hit 'blue-sky' caseOctober 5 at 12:42 AM | msn.comVaxcyte stock falls on $1B dual offering launchOctober 5 at 7:42 PM | finance.yahoo.comVaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notesOctober 5 at 7:42 PM | msn.comSee More Vaxcyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email. Email Address About VaxcyteVaxcyte (NASDAQ:PCVX) (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products. Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes. These candidates are being developed for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. The company is also advancing additional vaccine programs targeting other bacterial pathogens, although its pipeline remains focused primarily on pneumococcal disease. Founded in 2013 as SutroVax and renamed Vaxcyte in 2020, the company is headquartered in San Carlos, California. Vaxcyte is developing its vaccine candidates for potential use in global markets and does not currently have a marketed commercial product. Grant Pickering, Ph.D., serves as the company’s chief executive officer.View Vaxcyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
